JPRN-jRCT2033220602进行中（未招募）未知
Continuous observation study after administration of ADR-001 in patients with Compensated Liver Cirrhosis
Terai Shuji0 个研究点目标入组 9 人开始时间: 2023年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Patients who received at least one dose of ADR-001 in the ADR-001-N1 Study.
- •2)Patients capable of giving written informed consent.
排除标准
- •1)Patients decided to be ineligible for this study by the investigator.
研究者
相似试验
招募中
不适用
Observational study to check the effectiveness and safety of Remoglifozin in high risk patients with type 2 Daibetes Mellitus.CTRI/2022/01/039072Torrent Pharmaceuticals Ltd
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SIntravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365EUCTR2005-004105-28-GRPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative ColitisIntravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365EUCTR2005-004105-28-NLPDL BioPharma, Inc300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SEUCTR2005-004105-28-DEPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SEUCTR2005-004105-28-FRPDL BioPharma, Inc.300